Prima BioMed Ltd (NASDAQ:IMMP) Short Interest Down 36.4% in August

Posted by Brenda Bartman on Sep 1st, 2026

Prima BioMed Ltd (NASDAQ:IMMP – Get Free Report) saw a large drop in short interest in August. As of August 14th, there was short interest totaling 760,586 shares, a drop of 36.4% from the July 30th total of 1,195,547 shares. Based on an average daily volume of 136,177 shares, the short-interest ratio is currently 5.6 days. Currently, 0.5% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on IMMP. Maxim Group upgraded shares of Prima BioMed from a “hold” rating to a “buy” rating in a report on Wednesday, June 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Prima BioMed in a report on Friday, July 10th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $5.50.

View Our Latest Report on IMMP

Prima BioMed Stock Up 1.4%

Shares of Prima BioMed stock traded up $0.01 on Tuesday, reaching $0.37. 91,787 shares of the company were exchanged, compared to its average volume of 5,724,057. Prima BioMed has a fifty-two week low of $0.29 and a fifty-two week high of $3.53. The stock has a fifty day moving average price of $0.40 and a 200-day moving average price of $0.78.

Prima BioMed (NASDAQ:IMMP – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The biotechnology company reported ($0.09) earnings per share for the quarter. The company had revenue of $3.68 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Prima BioMed stock. Jane Street Group LLC increased its position in shares of Prima BioMed Ltd (NASDAQ:IMMP – Free Report) by 14.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,574 shares of the biotechnology company’s stock after acquiring an additional 6,617 shares during the quarter. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 as of its most recent SEC filing. Institutional investors and hedge funds own 2.32% of the company’s stock.

Prima BioMed Company Profile

(Get Free Report)

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.